Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR1 |
Variant | K687E |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR1 K687E (corresponds to K656E in the canonical isoform) lies within the protein kinase domain of the Fgfr1 protein (UniProt.org). K687E has been identified in the scientific literature (PMID: 32622884, PMID: 34250399, PMID: 35952322), but has not been biochemically characterized and therefore, its effect on Fgfr1 protein function is unknown (PubMed, Oct 2024). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR1 mutant FGFR1 K687E |
Transcript | NM_001174067.2 |
gDNA | chr8:g.38414790T>C |
cDNA | c.2059A>G |
Protein | p.K687E |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001174067.1 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
XM_011544445.2 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
XM_011544447.3 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
NM_001174067.2 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
XM_011544447.2 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
XM_011544444.2 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
XM_011544445.3 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
XM_011544444.1 | chr8:g.38414790T>C | c.2059A>G | p.K687E | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 M563I FGFR1 K687E | oligodendroglioma | predicted - sensitive | Futibatinib | Case Reports/Case Series | Actionable | In a Phase I trial (FOENIX-101), Lytgobi (futibatinib) treatment resulted in a partial response in a patient with anaplastic oligodendroglioma harboring FGFR1 M563I and FGFR1 K687E (PMID: 32622884; NCT02052778). | 32622884 |
FGFR1 V592M FGFR1 K687E | pilomyxoid astrocytoma | predicted - sensitive | Zoligratinib | Case Reports/Case Series | Actionable | In a clinical case study, Debio 1347 treatment resulted in a significant clinical improvement and sustained stable disease at 14 months with a 12.2% maximal tumor reduction in a pediatric patient with optic pathway pilomyxoid astrocytoma harboring FGFR1 V592M and FGFR1 K687E (PMID: 34250399). | 34250399 |
FGFR1 V592M FGFR1 K687E | glioblastoma | predicted - sensitive | Zoligratinib | Case Reports/Case Series | Actionable | In a clinical case study, Debio 1347 treatment resulted in a near complete response with a 96.3% maximal tumor reduction after 2 months of therapy in a pediatric patient with spinal cord glioblastoma harboring FGFR1 V592M and FGFR1 K687E, and the response was maintained for 11 months (PMID: 34250399). | 34250399 |